Sellas Life Sciences Group Inc SLS

US Biotechnology

$11.51 ▼ -0.69% ($-0.08)

🔥 High Short Interest 🎢 High Beta

Open $11.50

Prev Close $11.59

Day Range $11.37 – $11.64

52W Range $1.39 – $15.88

Market Cap $2.32B

Beta 2.72

EPS (TTM) $-0.22

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2008-03-12
Shares Out.	196,630,000
Website	sellaslifesciences.com/ ↗
Phone	16462005278
Employees	13
Revenue	$0
Gross Profit	$0
Net Income	-$9.6M
Free Cash Flow	-$28.4M
Total Assets	$145.4M
Total Liabilities	$7.7M
Equity	$137.7M

About Sellas Life Sciences Group Inc

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Sellas Life Sciences Group Inc is a publicly traded company under the ticker symbol SLS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.